Gyre Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Gyre Therapeutics, Inc. (GYRE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $17.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-13
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $17.60M, a 83.33% increase from fiscal 2024.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $9.60M, a 9500.00% increase from fiscal 2023.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $100.00K.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $3.00K, a 97.00% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|
| 2025-12-31 | $17.60M 10-K · filed 2026-03-13 | |
| 2024-12-31 | $9.60M 10-K · filed 2026-03-13 | |
| 2023-12-31 | $100.00K 10-K · filed 2025-03-17 | |
| 2021-12-31 | $3.00K 10-K · filed 2023-03-30 | |
| 2020-12-31 | $100.00K 10-K · filed 2022-03-31 | $116.00K 10-K · filed 2021-03-04 |
| 2019-12-31 | $159.00K 10-K · filed 2021-03-04 | |
| 2018-12-31 | $213.00K 10-K · filed 2020-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |